DNA Interference

ProNAi To Present Phase II Clinical Data For New Cancer DrugProNAi Therapeutics Inc., a developer of drugs that target cancer by interfering with cancer cells' DNA, announced that data from its ongoing Phase II clinical study of its drug candidate PNT2258 will be presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans Dec. 7-10.
ProNAi Presents Cancer Drug Results, Expands Management TeamProNAi Therapeutics Inc., a cancer drug development company, said last week that it had concluded its initial human clinical trial of PNT2258, a new type of nucleic acid drug.